Accelerated proliferation of myeloma cells by interleukin-6 cooperating with fibroblast growth factor receptor 3-mediated signals
- PMID: 15940250
- DOI: 10.1038/sj.onc.1208782
Accelerated proliferation of myeloma cells by interleukin-6 cooperating with fibroblast growth factor receptor 3-mediated signals
Abstract
Interleukin-6 (IL-6) is a cytokine that regulates the proliferation of some tumor cells including multiple myeloma (MM). Ectopic expression of fibroblast growth factor receptor 3 (FGFR 3) associated with the chromosomal translocation, t(4;14)(p16.3;q32), is frequently found in MM, and therefore, has been implicated in the neoplastic transformation of this disease. Here, we show that IL-6 together with FGF enhanced proliferation of a myeloma cell line, KMS-11 carrying t(4;14)(p16.3;q32) and the FGFR 3-transfected U 266 myeloma cell line which ectopically expressed FGFR 3 but responded to neither IL-6 nor FGF alone. In KMS-11, IL-6 activated signal transducer and activator of transcription 3 (STAT 3) while FGF activated extracellular signal-regulated kinase 1/2 (ERK 1/2) and phosphatidylinositol (PI)-3 kinase. As both MEK inhibitors and a PI 3-kinase inhibitor abolished the effect of IL-6 and FGF, the activation of both the ERK 1/2 and PI 3-kinase signaling cascades is essential for the proliferation of KMS-11 enhanced by IL-6 and FGF. Furthermore, the FGF-induced activation of ERK 1/2 contributed to the serine phosphorylation of STAT 3, suggesting that the signaling crosstalk between the cytokine receptor, IL-6 receptor alpha/gp 130 and the growth factor receptor tyrosine kinase, FGFR 3. These results indicate that FGFR 3 plays a crucial role in the accelerated proliferation of MM carrying t(4;14)(p16.3;q32).
Oncogene (2005) 24, 6328-6332.
Similar articles
-
Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.Oncogene. 2006 Sep 28;25(44):6003-14. doi: 10.1038/sj.onc.1209592. Epub 2006 May 8. Oncogene. 2006. PMID: 16682955
-
Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.Clin Cancer Res. 2005 Apr 1;11(7):2702-12. doi: 10.1158/1078-0432.CCR-04-2057. Clin Cancer Res. 2005. PMID: 15814652
-
A novel signaling pathway associated with Lyn, PI 3-kinase and Akt supports the proliferation of myeloma cells.Biochem Biophys Res Commun. 2010 Feb 12;392(3):415-20. doi: 10.1016/j.bbrc.2010.01.038. Epub 2010 Jan 15. Biochem Biophys Res Commun. 2010. PMID: 20079716
-
Mitogenic signals initiated via interleukin-6 receptor complexes in cooperation with other transmembrane molecules in myelomas.J Clin Exp Hematop. 2006 Nov;46(2):55-66. doi: 10.3960/jslrt.46.55. J Clin Exp Hematop. 2006. PMID: 17142955 Review.
-
Principles of interleukin (IL)-6-type cytokine signalling and its regulation.Biochem J. 2003 Aug 15;374(Pt 1):1-20. doi: 10.1042/BJ20030407. Biochem J. 2003. PMID: 12773095 Free PMC article. Review.
Cited by
-
Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b.Haematologica. 2010 Feb;95(2):260-9. doi: 10.3324/haematol.2009.012088. Epub 2009 Aug 27. Haematologica. 2010. PMID: 19713220 Free PMC article.
-
A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells.Hum Mol Genet. 2009 Jun 1;18(11):1951-61. doi: 10.1093/hmg/ddp116. Epub 2009 Mar 13. Hum Mol Genet. 2009. PMID: 19286672 Free PMC article.
-
Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.Blood. 2008 Sep 15;112(6):2439-49. doi: 10.1182/blood-2008-05-159392. Epub 2008 Jul 9. Blood. 2008. PMID: 18614762 Free PMC article.
-
Interleukin 6 and cancer resistance in glioblastoma multiforme.Neurosurg Rev. 2024 Sep 5;47(1):541. doi: 10.1007/s10143-024-02783-5. Neurosurg Rev. 2024. PMID: 39231832 Review.
-
The role of interleukin-6 in malignant mesothelioma.Transl Lung Cancer Res. 2015 Feb;4(1):55-66. doi: 10.3978/j.issn.2218-6751.2014.07.01. Transl Lung Cancer Res. 2015. PMID: 25806346 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous